The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Ffs let's have some bad news tomorrow then this might go up!
Nothing is going to move this SP up based on break even & profit 2025 comment! Well done Barder you Fwit. Should have just said revenue growth through 2024 onwards with peak sales expected after 5years of £xx!
Quick search for latest FUM news and it’s only Proactive picking this up. There in lies the problem, poor media relations.
"With this sign-off, the erectile dysfunction (ED) product can be sold in Mexico without a prescription. It plugs the Futura's fast-acting gel into a large new market, building on the success it has seen in the UK and Belgium."
On Proactive an hr ago.
Looking over thee curve?
I interpret that (ref Uk and Belgium )as currently (now) as well.
It is for sale in many outlets now (Asda online etc.) Boots still selling good as an incremental (probs repeats, which will prove to be the Sp fwd catalyst)
I think peeps will be surprised and caught out at Q4R myself, like at Q2R?
That is my Crystal Ball fwd take.
I think a lot will be left in the Stalls big time after the Horse has bolted!
We shall see.
USA sales will spin off plenty of cash. No more fundraising here. Lots of upside and limited downside at this level now.
Lol.
It was signed over 2yrs ago.
I note another variant as per different deals.
Similar to Haleon.
Royalties on all sales!
Thanks darkyhorse.had completely forgotten this. old age im afraid!
Futura to receive payments on all sales of MED3000 from m8 Futura also eligible to receive up to $8.5 million in milestone payments based on deliverable sales volumes, including a small initial upfront payment m8 is responsible for all local MED3000 development and regulatory costs in Brazil and Mexico as well as marketing expenses and ongoing pharmacovigilance and safety within the region m8 is a specialty biopharmaceutical company, headquartered and incorporated in the USA and focused on licensing, marketing and distributing innovative and established therapeutics in the two largest Latin America markets: Brazil and Mexico.
Under the terms of the agreement Futura and m8 will work together to gain marketing authorisation and commercialise MED3000 as a clinically proven treatment for ED available without the need for a doctor's prescription ("OTC") in Brazil and Mexico, the two biggest countries and healthcare end markets in Latin America. The agreement is for an initial term of 15 years.
m8 will be responsible for all costs related to the regulatory approval and marketing of the product. m8 and Futura believe the EU (inclusive of the UK) approval of MED3000 granted in April 2021 will facilitate approval in Brazil, Mexico and other countries within Latin America without the need for further clinical development. Futura will provide reasonable ongoing technical support for OTC product development and commercialisation. Futura will receive payments on all sales of MED3000 from m8, and up to four milestone payments totalling $8.5 million based on cumulative sales volumes within the initial term.
Bit by bit they are building a global brand
Its all about distribution .Think gillette and coca cola
Combined US and Mexico launch perhaps? US manufacturing partner? US listing?
So many possibilities and such huge potential, this has got to fly soon.
Yes excellent news. i note the RNS refers to M8 .not 100%sure but i don't recall hearing about them before.happy to be corrected https://www.m8pharmaceuticals.com/
Great news, wonder how long it will take to launch and how much M8 will price it at. Varying prices it is sold at around the world is interesting, I would imagine FUM leave that decision to all their partners, share price I believe will move quickly once the seller has disappeared.
Futura Medical PLC Eroxon(R) Granted Marketing Authorisation in Mexico - nice start for the day.
But I won't hold my breath that the share will rise signficantly......but yet an another peace of the puzzle completed
Https://www.binsina.ae/en/buy-eroxon-4-tubes-gel.html approx £36.aplogies if this has already been posted.
Nothing to be concerned about here. With all new regions coming on board, there will be Hugh amounts going on behind the scenes. 2024 will be the year for FUM. The only way it up! Just got to hold tight for the foreseeable, & all will start to align, have faith. Brand building & logistics take time to build. Fill up at this amazing! SP all is good! I can't see a take over! there is no need. If they were struggling to network & didn't have the scale out ability then maybe. But all is rolling out. Patience peeps! Patience & more patience!
Share price kept lows as all offers mention the premium to the previous three months share price.
I think they will be hard pressed to reject an all cash offer of say 90p
Lets see
Simple really A sells shares to B
JB has previously mentioned they might look at a trade sale.
Makes much more sense for Fum to be part of a much larger co with global distribution
tick tock
Ahananda - Please amplify and how you see this working in practice
It is entirely possible Lombard sells its stake to Haleon.
Much cheaper way for Haleon to benefit from eroxon
One needs constantly to bear in mind that L/O own 28.5%%. imo they will want an exit strategy at some point,but i doubt it will be low ball.personally im looking for at least 100p per share
There was a stock overhang from Co high and shorts took advantage of it.
Overhangs clear and there is a lot of newsflow ahead
Average price target is around 130p
This is it!!!
All the ducks are lined up.
Strap yourselves in.
Last train leaving the station.
Rocket to the moon!
I wish I believed my own statements and was brave enough to buy more..
I feel this is being set up for a takeover.
Current management seems to want to take the money, let the share price dive and wait for an attractive offer of X amount, which us frustrated and tired LTH will begrudgingly accept.
Oh sorry I need to make a correction they’ve already issued themselves with multi million pound bonuses of half a £mill shares each, which ultimately comes out of our pockets! Nice could they not wait!
DandD - it was a very inexperienced, some might say, amateur comment which experienced FD’s and CEO’s would not make. This is one of the reasons why some short termer’s have sold down, as well as a larger seller. It was a completely unnecessary and damaging statement and indeed why can they be so sure when so little sales data has been made available for them to see through and assess profitability that far out!. Anyone would think they wanted the price down to award nil cost options! They are signing new contracts each month so what about the sales from those relationships in new jurisdictions in 2024 and UK/Europe for this year and next?. I have a large investment here and when I read this pronouncement I should have sold down as others clearly have, but decided I would tough it out. I wonder what our Chairman is doing to reign Barder and the FD in from making inane statements like that going forward. Hire someone savvy enough to deal with the markets for goodness sake. To the poster who asked for justification as to why senior management are not doing a good job perhaps you should reflect upon what I have said and the collapse of the share price thereafter! Private investors are ignored by Barder ( at least I have been) but I do hope that the Portfolio Manager at Lombard Odier has picked up the phone and explained that Barder and the FD should apply for an Investors relations course tout de suite otherwise they will be voted out quicker that you can say Eroxon.
I’m struggling to understand this break even comment in 2024 & profitable in 2025! Where are FUM planning on spending their profits in 2024? Can anyone answer this? Are they planning on giving themselves multi million pound bonuses?